 |
8 Diseases |  |
17 Trials |
|
17 Trials |  |
2602 News |  |
| «12...56789101112131415...2425» |
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Higher prevalence of spinal cord relapses after treatment with alemtuzumab (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2408;
After a mean of more than 2 years of follow up, the 90,2% of our patients has not needed to be retreated with additional courses of alemtuzumab. Although the relapse rate after ALZ is very low, we´ve observed a higher prevalence (75%) of spinal cord relapses and this data is not describe in literature.
- Campath (alemtuzumab) / Sanofi, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world evidence of immune reconstitution therapies: use of Cladribine and Alemtuzumab in Chile (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2392;
Special concerns are raised in patients switching from fingolimod to CLAD. Infections seem equivalent in both groups, while more patients developed secondary autoimmunity after ALEM.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2391;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2376;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2367;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world effectiveness of alemtuzumab in RRMS patients in Germany: Interim results of the TREAT-MS study after completion of recruitment (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2356;
The current results indicate that alemtuzumab is effective in the real-world setting in patients with different treatment histories and longer treatment duration. Study support: Sanofi.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] micro-RNA expression profile in PBMCs changes after alemtuzumab treatment in patients with relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2344;
Pro- and anti-inflammatory miRNAs are simultaneously upregulated during the first 6 months after treatment suggesting a broad activation of monocytes as part of the reorganization process. Within 12 months this inflammatory cascade appears to subside.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Observational study of a novel peri-infusion regimen on the infusion-associated reactions with alemtuzumab in patients with MS in a Canadian clinical setting (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2327;
This protocol was associated with no serious IARs. While most pts had at least one potential vital sign abnormality, none were of clinical significance.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A disease modifying therapy panel for multiple sclerosis: experience of the first 2 years (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2322;
The NI DMT Panel meeting has facilitated timely consideration of escalation/high efficacy therapies in a collaborative environment, allowing open review of clinical/MRI data and application of prescribing guidelines. A rolling assessment of outcomes and practices is ongoing.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Management of intravenous therapy for MS during COVID-19 pandemic (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2316;
Patient on antiCD20 therapy seems to be at higher risk from most serious Covid-19 disease. PCR is a useful tool to prevent from virus shedding at day hospital.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Blood pressure excursions with alemtuzumab in Canadian patients with relapsing remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2310;
Alemtuzumab infusion was associated with a general hypotensive effect, though frequent sustained hyper- and hypotensive excursions also occurred with a peak incidence on Day 4. Hypertensive excursions were relatively rare in patients with elevated baseline SBP.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Persistence of seroprotective titers of antibodies against HBV and VZV in MS patients (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2305;
DMT’s might influence the persistence of antibodies against HBV after successful immunization; in our sample, anti-CD20 drugs were associated with an 11-fold increased risk of losing seroprotection in the first years of treatment. Long-term outcomes of VZV vaccination were not influenced by DMT treatment.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Can induction of autoimmune antibodies after alemtuzumab treatment of multiple sclerosis predict secondary autoimmunity? (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2301;
Smoking was also a risk factor of SAD. In contrast, non-thyroid auto-Abs were not helpful in predicting NTSAD.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Risk of cancer with disease-modifying drugs in multiple sclerosis: a new-user cohort design in the French nationwide claims database (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2293;
Results suggest a trend of increased risk of cancer in patients with MS who initiated IS compared with IIM. Longer follow-up of this patient population is warranted.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Hemophagocytic lymphohistiocytosis and alemtuzumab: a rescue or a cause? (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2267;
Albeit rarely, HLH can be triggered by ALM treatment for various diseases, such as HA-RRMS. Neurologists should be aware of this potentially lethal condition which can favourably respond to prompt immunosuppressant therapy.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2252;
In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Additional courses of alemtuzumab in sub-optimal responder multiple sclerosis patients are safe and effective: experience from 15 Italian MS centers (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2248;
Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells. Despite the limitations of a retrospective study and the small number of patients, our study confirms that additional ALZ courses in MS are safe and can effectively lengthen control of disease activity, representing a valid option for patients with a sub-optimal therapeutic response.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2235;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Alemtuzumab-related lymphocytes subset dynamics and disease activity or autoimmune adverse event (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2234;
We found a potential association between CD8 lymphocytes and clinical relapses. A longer follow up could better define the possible role of lymphocyte subsets in predicting disease reactivation.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2223;
Rituximab could be an effective and safe treatment in RRMS, including aggressive forms of the disease. Some selected PMS patients could also benefit from this treatment.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2222;
Quantifying post-vaccination IgG response across DMTs is crucial to optimize MS management. Data from ongoing sample collection will be presented at the meeting.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Humoral and cellular immune responses to SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2220;
Preliminary results show altered protective humoral immunity in MS patients treated with rituximab and fingolimod. Continuous analysis of cellular immunity is conducted in these patients.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2159;
sNFL levels increased with aging across both in healthy control and pwMS, although it was more pronounced among PMS patients, albeit absence of disease activity and treatment. This may suggest that ongoing degeneration is largely unaffected by current treatments.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2142;
In this small observational study of pwMS undergoing two CSF NfL measurements, factors reflecting early disease stage were associated with more pronounced drop in CSF NfL after starting immunotherapy explaining separately between 12 and 21% of the variation in CSF NfL levels. These observations suggest a stronger neuroprotective effect of such treatment when used early in the course of MS.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Socioeconomic Status and MS disease severity in Chile (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1868;
Public health patients, as a proxy for SES and being diagnosed before 2016 as a proxy for high-efficacy DMT delay are independent risk factors for increased disease severity. Changes in public policies such as early diagnosis and universal access to high-efficacy DMT improve outcomes in MS.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1834;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in a neuroimmunology and multiple sclerosis referral unit (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1804;
Los datos de nuestra serie estan en concordancia con otros estudios, mostrando que la esclerosis múltiple per se y los diferentes tratamientos immunomoduladors no son un factor de riesgo para el COVID19. Es importante acelerar la vacunación de los pacientes con esclerosis múltiple para reducir la posibilidad de infección por SARS-CoV-2.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] SARS-COV-2 infection impact on patients with multiple sclerosis and neuromyelitis spectrum disorder in a Colombia cohort (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1802;
35% received Natalizumab, 19% Fingolimod, 15% Ocrelizumab, 8% Alemtuzumab, and 8% Rituximab; 15% were not receiving DMT, and 27% had received the last dose of their respective DMT in the previous 30 days[IA1] . Clinical outcomes of COVID infection in patients with MS and NMOSD did not differ from what is reported in similar studies in Latin-American population.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1711;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. (Pubmed Central) - Sep 22, 2021
Baseline gradients - but not lesion loads or brain volumes - may predict on-treatment relapses. Larger confirmatory studies are required.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Risk of invasive fungal infections among patients treated with disease modifying treatments for multiple sclerosis: a comprehensive review. (Pubmed Central) - Sep 22, 2021
Papers evaluating the following drugs were reviewed: rituximab, ocrelizumab, alemtuzumab, fingolimod, natalizumab, dimethyl fumarate, interferon, glatiramer acetate, cladribine, teriflunomide.Expert opinion: Overall, the occurrence of invasive fungal infections was low, with most infective events reported among patients treated with monoclonal antibodies and fingolimod...Although not common, these infections may be difficult to diagnose and their fatality rate is often high. For this reason, screening protocols for fungal infections must be implemented in the clinical practice when managing patients with MS.
- | Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Preclinical, Journal: A cell-based assay for the detection of neutralizing antibodies against alemtuzumab. (Pubmed Central) - Sep 16, 2021
In this proof-of-concept study, a CHO-CD52 cell line has been developed and used to detect the presence of anti-alemtuzumab neutralizing antibodies. This platform provides the basis of an assay for routine screening of serum for neutralizing antibodies from patients treated with alemtuzumab.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Detecting and predicting neutralization of alemtuzumab responses in MS. (Pubmed Central) - Sep 15, 2021
Monitoring of lymphocyte depletion and the antidrug response may be of practical value in patients requiring additional cycles of alemtuzumab. ADA detection may help to inform on retreatment or switching to another treatment.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Severe paradoxical disease activation following alemtuzumab treatment for multiple sclerosis. (Pubmed Central) - Sep 15, 2021
ADA detection may help to inform on retreatment or switching to another treatment. No abstract available
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab. (Pubmed Central) - Sep 10, 2021
No abstract available No abstract available
- || Lemtrada (alemtuzumab) / Sanofi
It was only a year for my diagnosis and treatment (2018). My first 2 MS Specialists refused to diagnose and treat, before I went to UBC where i received immediate diagnosis and treatment. As of a year ago I am medication free (Lemtrada) you would never know I have MS (Twitter) - Sep 9, 2021
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal, HEOR: Pharmacoeconomic aspects of using cladribine (in tablets) for treatment of adult patients with remitting multiple sclerosis (Pubmed Central) - Sep 7, 2021
No abstract available In case of switching the patients, who are currently provided with other disease modifying drugs, to cladribine, in 4 years health budget will save up to 6284 million RUB (50.1%).
- fludarabine IV / Generic mfg., mitoxantrone / Generic mfg.
[VIRTUAL] Case of T-Cell Prolymphocytic Leukemia Successfully Treated with Fludarabine, Mitoxantrone, and Cyclophosphamide () - Sep 6, 2021 - Abstract #SOHO2021SOHO_689;
The patient presented in this case study was treated with conventional chemotherapy alone and achieved CR of T-PLL, maintaining the treatment response to date (3 months after completion of the therapy). Despite this, alemtuzumab remains a crucial element in the arsenal of treatment for T-PLL, and its lack of availability poses a serious challenge for clinicians.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). (Pubmed Central) - Aug 26, 2021
Despite this, alemtuzumab remains a crucial element in the arsenal of treatment for T-PLL, and its lack of availability poses a serious challenge for clinicians. This expert consensus approach provides physicians with some guidelines on optimizing the benefit/risk ratio when switching DMTs in patients with MS.
- || Lemtrada (alemtuzumab) / Sanofi
Yes please. My GP, very nicely, said it was a step too far unless my MS consultant suggested it. He did agree to simvastatin 80mg od. I have paused this in prep for the Alemtuzumab. Reduce load on my system as much as poss in the run up. (Twitter) - Aug 25, 2021
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study. (Pubmed Central) - Aug 24, 2021
In the future, linking these treatment sequences or other baseline characteristics with effectiveness and safety outcomes might be useful to support treatment decisions. Registered at Paul-Ehrlich-Institut under NIS 281.
- | Lemtrada (alemtuzumab) / Sanofi
Journal: Monoclonal antibody therapies for rapidly progressive and highly active multiple sclerosis in the era of the COVID-19 pandemic (Pubmed Central) - Aug 21, 2021
In this article, we pay special attention to monoclonal antibodies used for immune reconstitution therapy, which results in significant changes to the T-cell and/or B-cell repertoire. Based on the published data from registries in different countries, we attempted to estimate the benefits and risks of these therapies in a complicated epidemiological setting.
- ||| Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal, Adverse events: Alemtuzumab-induced Alopecia areata - a case report and systematic literature review of adverse events associated with Alemtuzumab. (Pubmed Central) - Aug 20, 2021
We also suggest pathomechanisms underlying these phenomena. To introduce this review, we present the case of a woman with RRMS who developed severe alopecia areata for the first time on alemtuzumab.
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Blood pressure changes during Alemtuzumab infusion for Multiple sclerosis Patients. (Pubmed Central) - Aug 14, 2021
To introduce this review, we present the case of a woman with RRMS who developed severe alopecia areata for the first time on alemtuzumab. This demonstrating significant increases in BP during alemtuzumab infusions in (PwMS).
- || Lemtrada (alemtuzumab) / Sanofi
Clinical, Review, Journal: Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients. (Pubmed Central) - Aug 12, 2021
AU must be considered among the secondary autoimmune manifestations of Alemtuzumab treatment. We emphasize the need for appropriate patient screening and thorough clinical surveillance for factors predisposing patients to secondary autoimmunity.
- || Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
Clinical, Journal: Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series. (Pubmed Central) - Aug 11, 2021
All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.
- || Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Review, Journal: Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. (Pubmed Central) - Aug 7, 2021
Serological status after vaccination is highly encouraged. Growing clinical evidence and continuous surveillance are extremely important to continue guiding future treatment strategies and vaccination protocols.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COMPARATIVE EFFECTIVENESS OF EARLY INTENSIVE OR ESCALATION TREATMENT STRATEGIES ON LONG TERM DISABILITY TRAJECTORIES IN RELAPSING MULTIPLE SCLEROSIS PATIENTS (Free Communication C) - Aug 6, 2021 - Abstract #WCN2021WCN_228;
EIT group included patients who received, as first DMT natalizumab, fingolimod, alemtuzumab, ocrelizumab, cladribine, mitoxantrone,. ESC group patients received the high efficacy DMT after ≥1 year of injectables DMTs, azathioprine, teriflunomide or dimethylfumarate treatment... Our findings indicate a higher effectiveness of EIT than ESC strategy in slowing disability worsening over time.
- | Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
Journal: COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry. (Pubmed Central) - Aug 6, 2021
In a population-based MS cohort, COVID-19 outcome was not associated with exposure to DMT and immunosuppressive DMT when accounting for other already known risk factors. This provides reassuring evidence that COVID-19 risk can be individually anticipated in MS and-except for a very small proportion of high-risk patients-treatment decisions should be primarily focused on treating MS rather than the pandemic.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Single cell analysis of cerebrospinal fluid leukocytes in treated multiple sclerosis patients (Stream 4 Pathogenesis) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1265;
Natalizumab affects trafficking in a lineage-specific fashion. Later stage MS affects multiple immune cell lineages in the CSF.